RecruitingPhase 2NCT06797518
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Iptacopan(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2025 – 2027
Study locations (15)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCLA Medical Center, Los Angeles, California, United States
- Central Florida Kidney Specialists, Orlando, Florida, United States
- Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
- CaRe Research, Chubbuck, Idaho, United States
- DaVita Clinical Research, Las Vegas, Nevada, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- OSU Wexner Medical Center, Columbus, Ohio, United States
- Prolato Clinical Research Center, Houston, Texas, United States
- Novartis Investigative Site, CABA, Buenos Aires, Argentina
- Novartis Investigative Site, Ashdod, Israel
- Novartis Investigative Site, Hadera, Israel
- Novartis Investigative Site, Haifa, Israel
- Novartis Investigative Site, Nahariya, Israel
- Novartis Investigative Site, Kuala Lumpur, Selangor, Malaysia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06797518 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital